CDC.govSwiss clinical-stage biotech Vaderis Therapeutics has raised $152 million in a Series B round to advance engasertib into Phase 3 for hereditary hemorrhagic telangiectasia (HHT). The financing, backed by a broad syndicate of specialist investors, gives the company a potentially decisive runway toward registration for a disease with no approved therapy.
Mimetas BVThe U.S. analytical technology group is acquiring a majority stake in Dutch organ-on-a-chip specialist MIMETAS, bringing human tissue models into its broader portfolio of multiomics, spatial biology and preclinical imaging. The deal is another sign that organoids and microphysiological systems are moving from specialized research tools toward integrated platforms for drug discovery.
Knowbio with Sweden.seSwedish rare-disease specialist Sobi is paying $75 million upfront for global commercial rights to Innate Pharma’s lacutamab, a first-in-class antibody targeting KIR3DL2 in cutaneous T-cell lymphoma. The deal gives Innate funding and a commercial partner for its next clinical step, while adding a late-stage oncology asset to Sobi’s rare-disease portfolio.
UK biotech Actimed Therapeutics has regained global rights to S-oxprenolol from the now-defunct Faraday Pharmaceuticals, giving it control of the experimental muscle-wasting drug across cancer cachexia, amyotrophic lateral sclerosis (ALS) and other potential indications.
Scottish biotech Mironid has raised $46 million (€40 million) in a Series B financing to advance MR-L45, its small-molecule candidate for autosomal dominant polycystic kidney disease (ADPKD) through clinical development.
French biotech Evexta Bio will combine its rupitasertib with Roche’s giredestrant in a Phase 1b trial targeting second-line, ESR1-mutated advanced breast cancer.
AstraZeneca has put Pathos AI in charge of the early clinical development of AZD4241, its preclinical ERα degrader for ER-positive, HER2-negative breast cancer, under a co-exclusive licensing agreement.
Ipsen confirmed to European Biotechnology that it has stopped developing the Phase 1/2a ERK inhibitor IPN01194 and will return worldwide rights to French biotech AGV Discovery.
Guido Oelkers will leave Swedish Orphan Biovitrum to become BioNTech’s CEO by Feb. 1, 2027, succeeding co-founder Uğur Şahin after overseeing a nine-year transformation that increased Sobi’s revenue more than fivefold.
AstraZeneca has held talks with Bristol Myers Squibb over a potential combination that would create a pharmaceutical group worth nearly $400 billion (€348 billion), the Financial Times reported.